Investor Satter Muneer A
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Satter Muneer A . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-02-14 13G/A AKBA / Akebia Therapeutics, Inc. 16,205,119 5,747,906
2025-02-14 13G/A WHWK / Whitehawk Therapeutics, Inc. 1,630,830 659
2024-04-16 13D/A RNTX / Rein Therapeutics Inc. 1,017,033 830,466
2024-03-05 13D/A RNTX / Rein Therapeutics Inc. 1,007,488 1,017,033
2024-02-09 13G/A AKBA / Akebia Therapeutics, Inc. 15,090,119 16,205,119
2023-11-03 13D/A RNTX / Rein Therapeutics Inc. 1,007,488
2023-02-17 13D/A ANNX / Annexon, Inc. 5,032,463 7,679,521
2023-02-10 13G/A AKBA / Akebia Therapeutics, Inc. 13,864,330 15,090,119
2023-02-10 13G/A AADI / Aadi Bioscience, Inc. 1,294,785 1,630,830
2022-12-19 13G AKBA / Akebia Therapeutics, Inc. 3,067,043 13,864,330
2022-10-04 13G AADI / Aadi Bioscience, Inc. 374,785 1,294,785
2022-07-18 13D ANNX / Annexon, Inc. 1,954,978 5,032,463
2022-02-10 13G/A ASMB / Assembly Biosciences, Inc. 2,227,500 2,227,500
2021-11-12 13D/A AADI / Aadi Bioscience, Inc. 5,621,835 374,785
2021-02-12 13G ANNX / Annexon, Inc. 1,954,978
2021-02-12 13G/A ALBO / Albireo Pharma Inc 832,000 0
2021-02-12 13G/A ASMB / Assembly Biosciences, Inc. 2,227,500 2,227,500
2021-01-08 13D/A ALRN / Rein Therapeutics Inc. 11,340,792 20,340,792
2021-01-04 13G ASMB / Assembly Biosciences, Inc. 2,227,500
2020-11-23 13D/A AADI / Aadi Bioscience, Inc. 5,621,835 5,621,835
2020-11-20 13D/A AADI / Aadi Bioscience, Inc. 5,621,835 5,621,835
2020-06-09 13D/A ALRN / Rein Therapeutics Inc. 7,640,792 11,340,792
2020-02-12 13G/A ALBO / Albireo Pharma Inc 832,000 832,000
2019-04-11 13D/A ALRN / Rein Therapeutics Inc. 7,640,792 7,640,792
2019-04-10 13D ALRN / Rein Therapeutics Inc. 7,640,792
2019-02-13 13G/A ALBO / Albireo Pharma Inc 832,000 832,000
2019-02-13 13G/A PDSB / PDS Biotechnology Corporation 1,814,000 0
2019-01-11 13D/A AADI / Aadi Bioscience, Inc. 5,078,017 5,621,835
2019-01-11 13D/A AKBA / Akebia Therapeutics, Inc. 3,067,043 3,067,043
2018-09-18 13D/A IMUX / Immunic, Inc. 11,597,719 215,442
2018-07-03 13D/A AKBA / Akebia Therapeutics, Inc. 3,054,542 3,067,043
2018-07-03 13D/A AADI / Aadi Bioscience, Inc. 5,078,017
2018-06-08 13D/A IMUX / Immunic, Inc. 11,034,688 11,597,719
2018-02-09 13G/A ALBO / Albireo Pharma Inc 830,000 832,000
2018-02-09 13G/A PDSB / PDS Biotechnology Corporation 1,800,000 1,814,000
2017-07-14 13D AKBA / Akebia Therapeutics, Inc. 2,007,560 3,054,542
2017-05-30 13G ALBO / Albireo Pharma Inc 830,000
2017-04-25 13G PDSB / PDS Biotechnology Corporation 1,800,000
2017-04-04 13D IMUX / Immunic, Inc. 7,254,449 11,034,688
2017-03-27 13D AADI / Aadi Bioscience, Inc. 3,241,835
2017-02-13 13G/A ELDN / Eledon Pharmaceuticals, Inc. 1,775,188 0
2017-02-13 13G/A IMUX / Immunic, Inc. 7,258,926 7,254,449
2017-02-13 13G/A AKBA / Akebia Therapeutics, Inc. 2,002,560 2,007,560
2016-02-12 13G/A IMUX / Immunic, Inc. 7,258,926
2016-02-12 13G/A ELDN / Eledon Pharmaceuticals, Inc. 1,775,188
2016-02-12 13G/A AKBA / Akebia Therapeutics, Inc. 2,002,560
2015-02-12 13G ELDN / Eledon Pharmaceuticals, Inc. 1,771,688
2015-02-12 13G AKBA / Akebia Therapeutics, Inc. 1,582,560
2015-02-12 13G IMUX / Immunic, Inc. 6,858,926
2014-02-14 13G/A HTWR / Heartware International Inc. 654,500
2013-02-14 13G/A HTWR / Heartware International Inc. 912,000
2012-02-14 13G/A HTWR / Heartware International Inc. 1,053,500